Biopharmaceutical company
Appears in 1 story
Developer of obicetrapib; retains rights outside Europe
The European Commission approved two obicetrapib-based cholesterol drugs on September 21, 2026. It's the first time any CETP inhibitor has reached the market, after Pfizer, Roche, Eli Lilly and Merck spent billions on the drug class and failed.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
